Belvedere Trading
RANI icon

Belvedere Trading’s Rani Therapeutics RANI Stock Holding History

Belvedere Trading’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-991
Closed -$3.77K – 885
2024
Q2 		$3.77K Buy
+991
New +$5.13K ﹤0.01% 627

Other funds holding RANI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

Belvedere Trading's RANI Position: Q3 2024 in Review

Belvedere Trading sold out of Rani Therapeutics (RANI) in Q3 2024, closing a stake of 991 shares — an estimated $3.77K sold.

Belvedere Trading first reported a position in RANI in Q2 2024 and held it in 1 quarter. The position peaked at $3.77K in Q2 2024. 31 funds tracked by Wall St. Rank hold RANI as of Q3 2024.

  • Belvedere Trading reported no remaining Rani Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Belvedere Trading sold 991 Rani Therapeutics shares in Q3 2024, an estimated $3.77K.
  • Belvedere Trading first reported a position in Rani Therapeutics in Q2 2024 and held it in 1 quarter.
  • Belvedere Trading's Rani Therapeutics position peaked at $3.77K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2024.

Based on Belvedere Trading's 13F filing for Q3 2024, filed 30 Oct 2024.